Sun, Dec 21, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Aquila Capital launches UCITS-compliant CTA fund that offers daily liquidity, Dr. Harry Kat new Quant Team’s Head of Research

Friday, September 16, 2011
Opalesque Industry Update – Aquila Capital launched a new, UCITS compliant CTA fund to the UK market today.

The AC Spectrum Fund is a liquid futures fund and is one of the first of its kind to offer daily rather than weekly liquidity. It is a fully systematic trend follower that targets a return of 18% to 20% per year with 15% volatility. The AC Spectrum Fund has shown strong performance in 2011. In the month of August the fund returned 9.88%, with a return of 9.44% since inception (¹).

The fund exploits a number of proprietary, rule based strategies that have been developed by the Aquila Capital Quant Team and masterminded by Prof. Dr. Harry M Kat, who has recently joined Aquila as the Quant Team’s Head of Research. Responsibility for the management of the AC Spectrum Fund lies with fund manager Dr. Jan Auspurg, who is supported by Dr. Dieter Rentsch, Harold Heuschmidt and the Quant Team.

Trend following is at the fund’s core but is supplemented with two additional strategies that are negatively correlated to the trend following strategy to create a more stable return stream over time.

Prof. Dr. Harry M Kat said:

“The Spectrum team combines long standing practical expertise with deep academic insights to create a unique product for Aquila Capital.

“Efficient diversification is one of the main pillars of AC Spectrum – the fund diversifies over markets as well as over fundamentally different strategies.”

Commenting on the appointment of Prof. Kat to Aquila full time, Roman Rosslenbroich, CEO and founder of Aquila Capital said:

“Prof. Kat is a world-renowned expert on alternative investments and a pioneer in hedge fund replication research. We’re delighted to welcome him to the team.”

(press release)

Prof. Dr. Harry M. Kat is Aquila Capital’s head of research. He holds a MSc and PhD in Economics and Econometrics from Tinbergen Graduate School of Business at University of Amsterdam and an expert for alternative investments and financial derivatives and a pioneer in hedge fund replication research. Prof. Dr. Harry M. Kat is a member of the Editorial Board at the Journal of Derivatives, the Journal of Alternative Investments and the Journal of Wealth Management. Previously, Prof. Dr. Kat was Director of the Alternative Investment Research Centre at Cass Business School in London, Head of Equity Derivatives Europe at Bank of America in London, Head of Derivatives Structuring and Marketing at First Chicago in Tokyo and Head of Derivatives Research at Mees Pierson in Amsterdam.

Dr. Jan Auspurg is a fund manager within Aquila Capital's quant team. Dr. Auspurg holds a doctorate in Management (Dr. oec. HSG) from the University of St. Gallen, Switzerland and has over 20 years of financial market experience. Previously, Dr. Auspurg worked for Salomon Brothers/Citigroup in Zurich and London, Bankers Trust in Zurich, J.P. Morgan in Zurich and London and Swiss Volksbank in Zurich.

AC Spectrum is a UCITS CTA that trades stock index, bond, interest rate, currency, and commodity markets around the world. It takes long and short positions in liquid futures markets. A fully systematic approach combines trend, carry and correlation strategies. AC Spectrum's proprietary conviction weighted position sizing and volatility equalization systems optimize the fund's multi-strategy approach and ensure efficient risk control. The Fund targets a return of 18% to 20% per year with 15% volatility.

Aquila Capital is a dynamic alternative investment company with $3.9bn under management, specializing in next-generation absolute return and real asset investment strategies including, but not limited to UCITS-III compliant funds. The company’s success is built on identifying and delivering market independent and uncorrelated investment solutions. Aquila Capital was founded in 2001 by Roman Rosslenbroich and Dieter Rentsch, who both have extensive experience in the international asset management arena. With over 60 investment specialists at Aquila Capital, the Company is head-quartered in Hamburg and supported by regional offices in Frankfurt and Zurich as well as the group’s structuring arm, Alceda Fund Management S.A. in Luxembourg. www.aquila-capital.de


See our 2008 articles on Harry Kat:
Opalesque Exclusive: Aquila Capital's multi-asset funds are up 1.9% and 1.0% in September, DWS and Aquila Capital launched a UCITS III CO2 fund Source
Opalesque Exclusive: Harry Kat`s FundCreator update says performance in line with expectations Source


BG

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. Opalesque Exclusive: U.S. legal receivables fund launched in August[more]

    Benedicte Gravrand, Opalesque Geneva for New Managers: Investing in asset-backed receivables is a strategy that has been an integral part of the alternative investment space within the overall fixed income asset c

  5. Comment - High fees and low performance hit hedge funds[more]

    From FT.com: Disenchantment over high fees and lackluster performance may finally be turning the tide against hedge funds, fresh data suggest. Despite generally weak returns since the global financial crisis, hedge funds have enjoyed positive net inflows every year since 2010. This helped assets und